AmbioPharm, one of the world’s largest capacity peptide development and manufacturing companies, is a generic peptide Active Pharmaceutical Ingredients (APIs) manufacturer and partner.
With our USA headquarters located in North Augusta, South Carolina and two facilities in Shanghai, China, we manufacture both new chemical entities and generic peptides under cGMP regulations for clients worldwide.
The US Food & Drug Administration (FDA) performs Pre-Approval Inspections (PAIs) and Regular Inspections of our three facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
We specialize in developing highly efficient manufacturing processes for peptide-based APIs from very small to very large scales and are a quality-focused CDMO.
AmbioPharm also partners with generic drug companies to develop generic peptide drugs for established commercial markets around the world.